In Q1 2026, Citius Oncology reported initial revenues of approximately $1.67 million from LYMPHIR, its sole FDA-approved oncology therapeutic launched in December 2025. Despite this commercial progress targeting a niche cutaneous T-cell lymphoma market valued over $400 million, the company continues to operate at a substantial loss and maintains a precarious liquidity position. Their business model leverages third-party manufacturing and a focused U.S. sales team supported by AI-driven commercialization tools, yet capital constraints pose execution risks. Sector dynamics favor LYMPHIR’s unique mechanism and NCCN guideline inclusion, but growth hinges on successful market adoption, reimbursement, and further capital infusion.